Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that the interim safety and efficacy results from the first 20 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma are as good as or better than Phase 1 data. Additionally, extended Phase 1 survival data was reported. To view Multimedia News Release go to http://www.prnewswire.com/mnr/pvct/37429/
Genre: News Videos
by: comments
Steve Benitez introduces Harimau: Phase 1, the new DVD from Reel Combat. This DVD gives you an introduction to the basic postures and principles of the Harimau (or tiger) style. Focusing on the first main posture, the basic blocks, strikes and jumps will give you an insight into this powerfully aggressive style.
Genre: Funny Videos
by: EastWestStudios
www.phasefidel.com
Genre: Entertainment
by: phasefidel
phasefidel.com
Women love being swept off their feet, emotionally and physically. This guy is so in love he picks his baby up and carries her like a queen. He probably should have gone to the gym first.
by: Break.com Staff
http://www.journeytotheinfinite.com/smallbusinesssuccess.html Heres the 2nd video in the series about opportunities in Phase 2 for playing The Business Game in very different ways -- increasing sales and profits and sales and marketing business success, but without all the stress, pressure and endless to do list.
Genre: How-to
by: Sternit12
http://www.journeytotheinfinite.com/smallbusinesssuccess.html Heres a video about opportunities in Phase 2 for playing The Business Game in very different ways -- increasing sales and profits and sales and marketing business success, but without all the stress, pressure and endless to do list.
C'mon...do you really think a little white powder is gonna phase the Lohan?
Genre: Celebs
by: MadisonHotels
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has announced interim data from the first 40 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma. PV-10 treatment was well tolerated and caused selective tumor destruction in the majority of subjects. Additional data on untreated tumors corroborated observations of a possible bystander effect seen during earlier Phase 1 testing. These data were presented today at the American Society of Clinical Oncology 2009 Annual Meeting, Abstract #9060, entitled “Chemoablation of melanoma with intralesional rose bengal (PV-10), in the General Poster Session.To view Multimedia News Release, go to http://www.prnewswire.com/mnr/pvct/37868/
